Figure 1


i.p. application of
phosphate-buffered saline
APN inhibitor actinonine (1 x 1 mg; then 0.5 mg/day)
DPIV inhibitor Lys[Z(NO2)] pyrrolidide (1 x 1 mg; then 0.5 mg/day)
Combination of APN and DPIV inhibitor (each 1 x 1 mg; then 0.5 mg/ day
EAE Score
4,0
3,5
3,0
2,5
2,0
1,5
1,0
0,5
0,0
0
10
20
30
40
50
Day of Experiment

Figure 2


i.p. application of
phosphate-buffered saline
APN inhibitor actinonine (10 µg/day)
DPIV inhibitor Lys[Z(NO2)] pyrrolidide (10 µg/day)
Combination of APN and DPIV inhibitor (each 10 µg/day)
Heaviness of the disease
12
10
8
6
4
2
0
*

Figure 3 A


A
OVA-sensitized animals: i.p. application of
phosphate-buffered saline
APN inhibitor actinonine
DPIV inhibitor Lys[Z(NO2)] pyrrolidide
Combination of APN and DPIV inhibitor (p=0.01)
Healthy, non-OVA-sensitized control group
Phosphate-buffered saline (placebo; p=0.01)
Reduction of EF50 (% below basal value)
-60
-50
-40
-30
-20
-10
0
*
**
A
B
C
D
E

Figure 3 B